Commodore Capital LP Buys Shares of 6,336,782 Perspective Therapeutics, Inc. $CATX

Commodore Capital LP purchased a new position in shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) in the 1st quarter, Holdings Channel reports. The firm purchased 6,336,782 shares of the company’s stock, valued at approximately $26,424,000. Perspective Therapeutics makes up approximately 1.5% of Commodore Capital LP’s portfolio, making the stock its 22nd biggest holding. Commodore Capital LP owned 0.06% of Perspective Therapeutics at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in CATX. Russell Investments Group Ltd. lifted its position in shares of Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after acquiring an additional 5,475 shares in the last quarter. Aigen Investment Management LP purchased a new position in Perspective Therapeutics in the 4th quarter valued at about $28,000. nVerses Capital LLC purchased a new position in Perspective Therapeutics in the 4th quarter valued at about $31,000. Abel Hall LLC acquired a new stake in shares of Perspective Therapeutics during the 1st quarter worth about $49,000. Finally, Engineers Gate Manager LP acquired a new stake in shares of Perspective Therapeutics during the 4th quarter worth about $35,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CATX has been the subject of a number of analyst reports. Wedbush reissued an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a research report on Friday. Eight equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Perspective Therapeutics presently has a consensus rating of “Buy” and an average target price of $12.62.

Perspective Therapeutics Stock Performance

NYSEAMERICAN CATX opened at $2.91 on Monday. The business’s 50-day moving average price is $3.31 and its 200 day moving average price is $3.90. Perspective Therapeutics, Inc. has a twelve month low of $1.96 and a twelve month high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. Perspective Therapeutics had a negative return on equity of 42.33% and a negative net margin of 17,982.69%.The company had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.16 million. As a group, research analysts anticipate that Perspective Therapeutics, Inc. will post -1.1 earnings per share for the current year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.